Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
60.25 USD | +1.50% | -7.82% | -27.94% |
13/05 | Transcript : Cytokinetics, Incorporated - Special Call | |
09/05 | Oppenheimer Adjusts Cytokinetics Price Target to $106 From $107, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.94% | 6.22B | |
+7.29% | 111B | |
+11.20% | 106B | |
-12.48% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.56% | 16.81B | |
+37.62% | 12.54B | |
-24.25% | 8.09B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- B. Riley Initiates Cytokinetics With Buy Rating, $66 PT; Says Aficamten's Differentiation Remains Underappreciated